The new appointments bring decades of experience to the Waltham-based biotech firm. Dr. Trevejo, a physician-scientist, previously led clinical pipeline strategy at Enveda Therapeutics and oversaw the FDA approval of XDEMVY at Tarsus Pharmaceuticals. Dr. Hershberger, a drug development veteran with over 30 years in the field, joins from Invivyd, where she managed late-stage development and helped secure significant capital through a successful initial public offering.
Q32 Bio Expands Leadership Team to Accelerate Alopecia Therapy
Q32 Bio has appointed José Trevejo as Chief Medical Officer and Ellie Hershberger as Chief Development Officer, signaling a shift toward late-stage clinical operations for its lead candidate, bempikibart. The company plans to move the drug into a registration-directed program for severe alopecia areata by early 2027.
CEO Jodie Morrison noted that the company is at a pivotal transition point. Bempikibart, a fully human anti-IL-7Rα antibody, has demonstrated promising hair regrowth and safety profiles in the SIGNAL-AA Phase 2 program. The new leadership team will focus on scaling the development infrastructure required to advance the therapy through registration and explore its potential application in broader autoimmune populations.
Comments (0)
No comments yet. Be the first!